oncozine.com valid

Automatically discovered from public files. Ownership management is optional. Inclusion does not imply endorsement or publisher participation.

Manage this listing — optional · Visit publisher ↗

Claim my listing on Agent Web Map for oncozine.com:
1. POST https://agentwebmap.com/v1/sites/oncozine.com/claims and keep claim_id and claim_secret private.
2. Publish the proof: add the line "AgentWebMap ownership: <token>" (token from step 1) to https://oncozine.com/llms.txt, or use the DNS, meta-tag or well-known method the response describes.
3. POST https://agentwebmap.com/v1/sites/oncozine.com/verify with {"claim_id": "...", "claim_secret": "..."}.
4. Save the api_key from the answer; it manages the listing (PATCH https://agentwebmap.com/v1/sites/oncozine.com).
MCP equivalent: tools begin_ownership_claim, then verify_domain, at https://agentwebmap.com/mcp. Docs: https://agentwebmap.com/docs#verify

Corrections or removal requests: contact the directory. Ownership management is optional.

Onco'Zine: International Oncology Network \- Cancer \& Hematology News

Onco'Zine is part of the Oncology and Hematology News Network that has been created to better inform physicians treating patients with cancer

Their llms.txt

The beginning of the file, from our validated copy saved 2026-10-21T18:12:55.540Z. Cached copy · Source on oncozine.com

# Onco'Zine: International Oncology Network \- Cancer \& Hematology News

> Onco'Zine is part of the Oncology and Hematology News Network that has been created to better inform physicians treating patients with cancer

Generated by Yoast SEO v28.7, this is an llms.txt file, meant for consumption by LLMs.

## Pages
- [Sunvalley Communication](https://www.oncozine.com/sunvalley-communication/)
- [Artificial Intelligence \(AI\) and Risk Assessment in Metastatic Hormone\-Sensitive Prostate Cancer\.](https://www.oncozine.com/artificial-intelligence-ai-and-risk-assessment-in-metastatic-hormone-sensitive-prostate-cancer/)
- [About Onco'Zine](https://www.oncozine.com/about-oncozine/about-oncozine-2/)
- [Schedule a Meeting](https://www.oncozine.com/schedule-a-meeting/)
- [Home](https://www.oncozine.com/)

## Posts
- [Mike Caligiuri Discusses Upcoming AACR Meeting, Cancer Health Equality, and Sudden Career Change](https://www.oncozine.com/mike-caligiuri-discusses-upcoming-aacr-meeting-cancer-health-equality-and-his-sudden-career-change/)
- [Oncoceutics Extends Patent Family to Include ONC201 In Leukemias](https://www.oncozine.com/oncoceutics-extends-patent-family-include-onc201/)
- [RiskScore Demonstrates Highly Statistically\-Significant Ability](https://www.oncozine.com/riskscore-demonstrates-highly-statistically-significant-ability-predict-5-year-lifetime-risk-breast-cancer/)
- [From Cold to Responsive: What Recent Clinical Advances Tell Us About Tumor Priming and Checkpoint Blockade](https://www.oncozine.com/from-cold-to-responsive-what-recent-clinical-advances-tell-us-about-tumor-priming-and-checkpoint-blockade/): Checkpoint inhibitors can only amplify an antitumor immune response that already exists, which is why immunologically “cold” tumors remain one of immuno\-oncology’s most persistent challenges\. Drawing on the recent U/S\. Food and Drug Administration's approval of vusolimogene oderparepvec\-wtpg \(Tudriqev™, formerly known as RP1; Replimune\), the intismeran autogene results, a negative BioNTech colorectal trial, and new preclinical data on GeoVax’s Gedeptin®, David A\. Dodd, Chairman, President and Chief Executive Officer of GeoVax Labs, and Kelly T\. McKee, Jr\., MD, MPH is Chief Medical Officer at GeoVax, argue that the next advances may come from pairing checkpoint blockade with therapies that first generate or strengthen the immune response worth unleashing\.
- [Engineering Salmonella Against Triple\-Negative Breast Cancer: UMass Amherst Awarded $13\.1 Million](https://www.oncozine.com/engineering-salmonella-against-triple-negative-breast-cancer-umass-amherst-awarded-13-1-million/): Engineered bacteria are moving from curiosity to a funded platform\. A five\-year, $13\.1 million National Institutes of Health \(NIH\) award to the University of Massachusetts Amherst will build nontoxic Salmonella strains that deliver three distinct therapies into drug\-resistant triple\-negative breast tumors\. The work is preclinical, but the published g
…

Related sites

Other listed sites in Media. See the whole category →

Help agents understand your site

Optionally manage your description, publish terms for agents, review file health, measured discovery requests, publisher clicks and score history. Confirm domain control in your browser using a fresh token in your llms.txt, DNS, meta tag or well-known file. No backlink is required.

Manage this listing → · Agent and API instructions

Machine-readable: GET /v1/resolve?q=oncozine.com · GET /v1/domain/oncozine.com · this page as Accept: application/json or text/markdown · MCP lookup_domain